spacer
home > ebr > winter 2018 > fight against resistance
PUBLICATIONS
European Biopharmaceutical Review

Fight Against Resistance

Microbial resistance to antibiotics is rising. Keiji Fukuda at the WHO has described antimicrobial resistance (AMR) as a major threat to global public health, stating “Without urgent, coordinated action by many stakeholders, the world is headed for a post-antibiotic era, in which common infections and minor injuries which have been treatable for decades can once again kill” (1). AMR is a natural and inevitable phenomenon, an outcome of natural selection; bacteria always have evolved to resist threats to their survival and will continue to do so. AMR cannot be completely prevented, but urgent action must be taken to curtail it and minimise its impact on global health.

Excessive and inappropriate use of antibiotics and antimicrobials more widely – combined with inadequate infection control and poor hygiene – are the main factors contributing to the spread of resistance, according to the European Commission’s statement on AMR (2). Decades of over-prescription and off-prescription use, in both humans and animals, have exacerbated the problem, and development of new antibiotics has all but stalled, with far fewer new drugs being licensed in the last couple of decades than in the early and mid-20th century.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Michele Barbour is Chief Executive Officer of Pertinax Pharma. Pertinax technology was developed by her research group at the University of Bristol, UK, where she is Reader in biomaterials and Deputy Head of Bristol Dental School, UK. Michele is the author of over 50 peer-reviewed publications and a leading textbook. She founded Pertinax Pharma in 2015 to commercialise the technology that allows the controlled and sustained release of the antiseptic chlorhexidine.
spacer
Dr Michele Barbour
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>

White Papers

Is Your Biobank Ready for the Challenge of Biomarker-based Research?

BioFortis

Targeted and personalized studies with well-defined patient segmentation biomarkers are becoming the norm in clinical trials. This increased interest in molecular biomarker studies necessitates a rigor and sophistication in sample management within the clinical trial context that is often not supported either by traditional clinical trial management software (CTMS), or biobanking systems.  Download our Next Generation Biobanking whitepaper and learn about how to overcome the key challenges in clinical trial sample management from working in a distributed network of partners and stakeholder to managing consents and generating scientific insights.
More info >>

 
Industry Events

PHARM Connect Congress 2018

13-14 March 2018, Corinthia Hotel Budapest, Hungary

PHARM Connect Congress is the premier networking business event dedicated to pharmaceutical and biotechnology innovations and trends from development through commercialization in Central and Eastern Europe and the CIS region. The two days event offers the perfect setting for solution providers to present their products and services directly to key decision makers playing a key role in the pharmaceutical industry in Central Eastern Europe.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement